MiniMed Group, Inc.

As of July 31, 2026, MiniMed Group, Inc. carries a market capitalization of 4.39B, placing it among publicly traded companies globally. Its enterprise value stands at 4.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MiniMed Group, Inc.'s next confirmed earnings release is scheduled for December 30, 2026.

As of July 31, 2026, MiniMed Group, Inc. has 281.21M shares outstanding.

These figures are as of July 31, 2026. The price-to-sales ratio is 1.57, and the price-to-book ratio stands at 1.40.

These figures are as of July 31, 2026. The EV/Sales ratio of 1.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.22B versus a market cap of 4.39B, with the gap driven by net debt and cash on the balance sheet.

As of July 31, 2026, MiniMed Group, Inc. maintains a current ratio of 1.81, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended July 31, 2026. The company generates approximately 349,264.80 in revenue per employee across its workforce of 8,000.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended July 31, 2026, MiniMed Group, Inc. recorded 111.00M in income tax expense. The company reported a pretax loss of -172.57M and -287.04M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026.

Over the twelve months ended July 31, 2026, MiniMed Group, Inc. generated 2.79B in revenue and converted that into -287.04M in net income, yielding earnings per share of -1.01. EBITDA reached -35.56M, while operating income came in at -163.03M.

As of July 31, 2026, MiniMed Group, Inc. holds 179.51M in cash and equivalents against 7.80M in total debt, resulting in a net debt position of -179.51M. Total book value stands at 3.14B, with working capital of 550.67M providing operational flexibility.

MiniMed Group, Inc. produced -91.06M in operating cash flow over the twelve months ended July 31, 2026. After subtracting -182.98M in capital expenditures, free cash flow totaled -274.04M - equivalent to -0.98 per share.

Over the twelve months ended July 31, 2026, MiniMed Group, Inc. posted a gross margin of 53.85, reflecting its pricing power and cost economics. The operating margin of -5.83 and net profit margin of -10.27 provide insight into operational efficiency.

These figures cover the twelve months ended July 31, 2026. Free cash flow yield is negative at -6.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.16, meaning MiniMed Group, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of July 31, 2026, MiniMed Group, Inc. has an Altman Z-Score of 4.12, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.